参考文献/References:
[1]Bosch NA,Cimini J,Walkey AJ.Atrial Fibrillation in the ICU[J].Chest,2018,154(6):1424-1434.[2]Hindricks G,Potpara T,Dagres N,et al.2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)[J].Eur Heart J,2021,42(5):373-498.[3]Lau DH,Nattel S,Kalman JM,et al.Modifiable Risk Factors and Atrial Fibrillation[J].Circulation,2017,13(6):583-596.[4]Goette A,Staack T,Rocken C,et al.Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation[J].J Am Coll Cardiol,2000,35(6):1669-1677.[5]Shen MJ,Zipes DP.Role of the autonomic nervous system in modulating cardiac arrhythmias[J].Circ Res,2014,114(6):1004-1021.[6]Wang WW,Zhang FL,Chen JH,et al.Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3K-Akt-eNOS pathways in spontaneously hypertensive rats[J].Can J Physiol Pharmacol,2015,93(8):657-665.[7]Chaugai S,Meng WY,Ali Sepehry A.Effects of RAAS Blockers on Atrial Fibrillation Prophylaxis:An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials[J].J Cardiovasc Pharmacol Ther,2016,21(4):388-404.[8]Rienstra M,Hobbelt AH,Alings M,et al.Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation:results of the RACE 3 trial[J].Eur Heart J,2018,39(32):2987-2996.[9]Gumprecht J,Domek M,Lip GYH,et al.Invited review:hypertension and atrial fibrillation:epidemiology,pathophysiology,and implications for management[J].J Hum Hypertens,2019,33(12):824-836.[10]Zhao Z,Yang Y,Wang J,et al.Combined treatment with valsartan and fluvastatin to delay disease progression in nonpermanent atrial fibrillation with hypertension:A clinical trial[J].Clin Cardiol,2020,43(12):1592-1600.[11]Yamabe H,Kaikita K,Matsumura T,et al.Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto:Atrial Fibrillation Suppression Trial (SILK study)[J].J Cardiol,2018,71(2):129-134.[12]Chen S,Acou WJ,Kiuchi MG,et al.Association of Preoperative Renin-Angiotensin System Inhibitors With Prevention of Postoperative Atrial Fibrillation and Adverse Events:A Systematic Review and Meta-analysis[J].JAMA Netw Open,2019,2(5):e194934.[13]Neefs J,van den Berg NW,Limpens J,et al.Aldosterone Pathway Blockade to Prevent Atrial Fibrillation:A Systematic Review and Meta-Analysis[J].Int J Cardiol,2017(231):155-161.[14]谭鹏进,商丽华,张涛,等.缬沙坦与螺内酯对心房颤动射频消融术后复发的影响[J].中国心脏起搏与心电生理杂志,2016,30(2):116-119.[15]Barone E,Di Domenico F,Butterfield DA.Statins more than cholesterol lowering agents in Alzheimer disease:their pleiotropic functions as potential therapeutic targets[J].Biochem Pharmacol,2014,88(4):605-616.[16]Chen WT,Krishnan GM,Sood N,et al.Effect of statins on atrial fibrillation after cardiac surgery:a duration- and dose-response meta-analysis[J].J Thorac Cardiovasc Surg,2010,140(2):364-372.[17]谭强,李广平,张双月,等.氟伐他汀预防阵发性心房颤动复发疗效观察[J].中华实用诊断与治疗杂志,2017,31(4):384-386．[18]Khan JA,Laurikka JO,Jarvinen OH,et al.Early postoperative statin administration does not affect the rate of atrial fibrillation after cardiac surgery[J].Eur J Cardiothorac Surg,2020,57(6):1154-1159.[19]Suleiman M,Koestler C,Lerman A,et al.Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation:a double-blind,placebo-controlled,randomized trial[J].Heart Rhythm,2012,9(2):172-178.[20]Colussi G,Catena C,Novello M,et al.Impact of omega-3 polyunsaturated fatty acids on vascular function and blood pressure:Relevance for cardiovascular outcomes[J].Nutr Metab Cardiovasc Dis,2017,27(3):191-200.[21]Mariscalco G,Sarzi Braga S,Banach M,et al.Preoperative n-3 polyunsatured fatty acids are associated with a decrease in the incidence of early atrial fibrillation following cardiac surgery[J].Angiology,2010,61(7):643-650.[22]Nodari S,Triggiani M,Campia U,et al.n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion:a prospective,randomized study[J].Circulation,2011,124(10):1100-1116.[23]Mariani J,Doval HC,Nul D,et al.N-3 polyunsaturated fatty acids to prevent atrial fibrillation:updated systematic review and meta-analysis of randomized controlled trials[J].J Am Heart Assoc,2013,2(1):e005033.[24]Macchia A,Grancelli H,Varini S,et al.Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation:results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial[J].J Am Coll Cardiol,2013,61(4):463-468.[25]Bhatt DL,Steg PG,Miller M,et al.Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia[J].N Engl J Med,2019,380(1):11-22.[26]McMurray JJ,Packer M,Desai AS,et al.Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure:rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)[J].Eur J Heart Fail,2013,15(9):1062-1073.[27]Ge Q,Zhao L,Ren XM,et al.LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis[J].Exp Biol Med (Maywood),2019,244(12):1028-1039. [28]von Lueder TG,Wang BH,Kompa AR,et al.Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy[J].Circ Heart Fail,2015,8(1):71-78. [29]Tsutsui H,Momomura S,Saito Y,et al.Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study[J].J Cardiol,2017,70(3):225-231.[30]De Vecchis R,Paccone A,Di Maio M.Favorable Effects of Sacubitril/Valsartan on the Peak Atrial Longitudinal Strain in Patients With Chronic Heart Failure and a History of One or More Episodes of Atrial Fibrillation:A Retrospective Cohort Study[J].J Clin Med Res,2020,12(2):100-107.[31]赵玉清,刘恒,杨亚楠,等.沙库巴曲缬沙坦联合胺碘酮治疗合并阵发性房颤的老年性心力衰竭的疗效观察[J].河北医药,2019,41(3):404-406,410.[32]钱丽群,徐莉苹,屠丽萍,等.上海某社区老年人心房颤动患者的调查[J].上海医药,2020,41(22):50-53.[33]刘晓勃,贾朝旭,夏时俊,等.不同临床特征低危心房颤动患者的血栓栓塞风险[J].中华心血管病杂志,2020,48(9):735-739.[34]Flannery MD,Kalman JM,Sanders P,et al.State of the Art Review:Atrial Fibrillation in Athletes[J].Heart Lung Circ,2017,26(9):983-989.[35]Larsson SC,Drca N,Wolk A.Alcohol consumption and risk of atrial fibrillation:a prospective study and dose-response meta-analysis[J].J Am Coll Cardiol,2014,64(3):281-289.
相似文献/References:
[1]姜亦瑶,王 凯,施 超.心肌纤维化引发心房颤动的研究进展[J].医学信息,2018,31(12):28.[doi:10.3969/j.issn.1006-1959.2018.12.010]
JIANG Yi-yao,WANG Kai,SHI Chao.Research Progress of Atrial Fibrillation Caused by Myocardial Fibrosis[J].Medical Information,2018,31(19):28.[doi:10.3969/j.issn.1006-1959.2018.12.010]
[2]张定欣,林先和.经食道三维超声在房颤二尖瓣结构变化对其
返流程度影响中的应用[J].医学信息,2018,31(12):76.[doi:10.3969/j.issn.1006-1959.2018.12.023]
ZHANG Ding-xin,LIN Xian-he.Application of Transesophageal Three-dimensional Ultrasound in the Influence of Mitral Valve Structure Changes on the Degree of Reflux in Atrial Fibrillation[J].Medical Information,2018,31(19):76.[doi:10.3969/j.issn.1006-1959.2018.12.023]
[3]王淑娟,林祥灿.血浆NT-proBNP水平与同型半胱氨酸对
糖尿病合并心房颤动的相关性研究[J].医学信息,2018,31(14):169.[doi:10.3969/j.issn.1006-1959.2018.14.053]
WANG Shu-juan,LIN Xiang-can.Correlation between Plasma NT-proBNP level and Homocysteine in Patients with Diabetes Mellitus Complicated with Atrial Fibrillation[J].Medical Information,2018,31(19):169.[doi:10.3969/j.issn.1006-1959.2018.14.053]
[4]陶春艳.柔性护理在胺碘酮治疗心房颤动护理中的应用研究[J].医学信息,2018,31(24):154.[doi:10.3969/j.issn.1006-1959.2018.24.046]
TAO Chun-yan.Application of Flexible Nursing in the Treatment of Atrial Fibrillation with Amiodarone[J].Medical Information,2018,31(19):154.[doi:10.3969/j.issn.1006-1959.2018.24.046]
[5]古俊楠,张牧秋,王建强,等.可穿戴设备在心房颤动诊治中的应用[J].医学信息,2019,32(15):34.[doi:10.3969/j.issn.1006-1959.2019.15.012]
GU Jun-nan,ZHANG Mu-qiu,WANG Jian-qiang,et al.Application of Wearable Devices in the Diagnosis and Treatment of Atrial Fibrillation[J].Medical Information,2019,32(19):34.[doi:10.3969/j.issn.1006-1959.2019.15.012]
[6]刘 瑜,王建强,古俊楠,等.房颤合并功能性二尖瓣返流研究[J].医学信息,2019,32(15):51.[doi:10.3969/j.issn.1006-1959.2019.15.017]
LIU Yu,WANG Jian-qiang,GU Jun-nan,et al.Study on Atrial Fibrillation Combined with Functional Mitral Regurgitation[J].Medical Information,2019,32(19):51.[doi:10.3969/j.issn.1006-1959.2019.15.017]
[7]张牧秋,古俊楠,刘 瑜,等.NOACS治疗房颤合并急性冠脉综合征的研究[J].医学信息,2019,32(13):28.[doi:10.3969/j.issn.1006-1959.2019.13.010]
ZHANG Mu-qiu,GU Jun-nan,LIU Yu,et al.Study of NOACS in the Treatment of Atrial Fibrillation Complicated with Acute Coronary Syndrome[J].Medical Information,2019,32(19):28.[doi:10.3969/j.issn.1006-1959.2019.13.010]
[8]王建强,刘 瑜,张牧秋,等.房颤伴ACS患者经皮冠状动脉介入术后抗栓研究[J].医学信息,2019,32(14):35.[doi:10.3969/j.issn.1006-1959.2019.14.013]
WANG Jian-qiang,LIU Yu,ZHANG Mu-qiu,et al.Study on Antithrombotic after Percutaneous Coronary Intervention in Patients with
Atrial Fibrillation and ACS[J].Medical Information,2019,32(19):35.[doi:10.3969/j.issn.1006-1959.2019.14.013]
[9]朱文书,张理想,游杨杨,等.长链非编码RNA MIAT表达水平与心房颤动导管消融术后复发的关系[J].医学信息,2021,34(04):75.[doi:10.3969/j.issn.1006-1959.2021.04.020]
ZHU Wen-shu,ZHANG Li-xiang,YOU Yang-yang,et al.Relationship Between the Expression Level of Long Non-coding RNA MIAT and Recurrence After Catheter Ablation of Atrial Fibrillation[J].Medical Information,2021,34(19):75.[doi:10.3969/j.issn.1006-1959.2021.04.020]
[10]马 利,李丽华.aVR导联法在心房颤动伴宽QRS波群心动过速鉴别诊断中的应用[J].医学信息,2022,35(19):142.[doi:10.3969/j.issn.1006-1959.2022.19.041]
MA Li,LI Li-hua.Application of aVR Lead Method in Differential Diagnosis of Atrial Fibrillation with Wide QRS Complex Tachycardia[J].Medical Information,2022,35(19):142.[doi:10.3969/j.issn.1006-1959.2022.19.041]